Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Audentes Therapeutics, Inc.BOLD · Entity 122788 | Senior VP & Chief Med Officer | June 05, 2019 | June 07, 2019 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | CMO and Head of R&D | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Audentes Therapeutics, Inc.
Report date June 05, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,479 |
Reported balance
After 2019-06-05 transaction · row 1
1 source rowRow 1 · 2019-06-05 · Tax withholding · Disposed 757 · Balance 17,479 F1: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes.
Taysha Gene Therapies, Inc.
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 530,589 |
Ending reported balance
After 2022-07-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-05 · Sale · Disposed 3,905 · Balance 539,545 F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Row 2 · 2022-07-06 · Sale · Disposed 8,956 · Balance 530,589 F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2022 Filed Jul 7, 2022 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 8,956 | $3.79 | $33,943.24 |
DisclosureSEC source: 0001209191-22-041455 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,589 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 3,905 | $3.51 | $13,706.55 |
DisclosureSEC source: 0001209191-22-041455 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,545 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 22:55 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 23,923 | $3.53 | $84,448.19 |
DisclosureSEC source: 0001209191-22-040356 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,450 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.82, inclusive. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 22:55 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 13,892 | $3.72 | $51,678.24 |
DisclosureSEC source: 0001209191-22-040356 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,373 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.81, inclusive. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 22:55 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 12,324 | $3.81 | $46,954.44 |
DisclosureSEC source: 0001209191-22-040356 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,265 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.64 to $3.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:26 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 40,325 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001209191-22-023862 · doc4.xml · derivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,325 Underlying: Common Stock · 40,325 shares Expires 2032-04-06 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on April 6, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 80,650 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001209191-22-013163 · doc4.xml · derivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,650 Underlying: Common Stock · 80,650 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 19,706 | $21.12 | $416,190.72 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 7 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,589 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.81 to $21.53, inclusive. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 500 | $23.70 | $11,850.00 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 6 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,295 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.00, inclusive. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 6,202 | $22.44 | $139,172.88 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 5 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,795 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.11, inclusive. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 13,374 | $21.42 | $286,471.08 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 4 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,997 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.13 to $22.11, inclusive. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 300 | $25.19 | $7,557.00 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,371 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.44, inclusive. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 3,862 | $24.46 | $94,464.52 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,671 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.04 to $24.95, inclusive. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:32 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 35,056 | $23.74 | $832,229.44 |
DisclosureSEC source: 0001209191-21-044563 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,533 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.04 to $24.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), (4), (5), (6), (7) and (8). Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:21 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004572 · doc4.xml · derivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-19 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:39 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionSeries B Preferred Stock · Derivative | 3,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052463 · doc4.xml · derivative · entry 2 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,844 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:39 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionCommon Stock | 3,844 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052463 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:14 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 668,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052116 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,745 F1 · shares: The shares underlying the RSU vest in 4 equal annual installments on each of June 29, 2021, June 29, 2022, June 29, 2023 and June 29, 2024, subject to the Reporting Person's continuous service as of each such vesting date F2 · price: Each RSU represents a contingent right to receive one share the Issuer's common stock. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:42 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 757 | $37.31 | $28,243.67 |
DisclosureSEC source: 0001209191-19-035588 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,479 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:42 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-19-030040 · doc4.xml · derivative · entry 4 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,870 Underlying: Common Stock · 10,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:42 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 54 | $37.72 | $2,036.88 |
DisclosureSEC source: 0001209191-19-030040 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,236 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:42 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 9,946 | $36.98 | $367,761.31 |
DisclosureSEC source: 0001209191-19-030040 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,290 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:42 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 10,000 | $0.79 | $7,900.00 |
DisclosureSEC source: 0001209191-19-030040 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-19-014074 · doc4.xml · derivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,870 Underlying: Common Stock · 10,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 10,000 | $30.06 | $300,553.00 |
DisclosureSEC source: 0001209191-19-014074 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,236 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.23. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 10,000 | $0.79 | $7,900.00 |
DisclosureSEC source: 0001209191-19-014074 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 48,750 | $0.00 Strike: $24.74 | $0.00 |
DisclosureSEC source: 0001209191-19-008671 · doc4.xml · derivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2029-02-06 F2 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008671 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,236 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 2/16ths of the award on June 5, 2019, and then 1/16th of the RSUs will vest on each of September 5, December 5, March 5 and June 5 thereafter until the RSUs are fully vested, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 18:37 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantCommon Stock | 736 | $19.64 | $14,451.36 |
DisclosureSEC source: 0001209191-18-059058 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736 F1 · kind: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and 16b-3(d). Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · derivative · entry 11 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,870 Underlying: Common Stock · 10,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 4,699 | $35.60 | $167,283.46 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 10 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.25 and the highest price at which shares were sold was $36.17. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 4,699 | $0.79 | $3,712.21 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 9 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 200 | $36.32 | $7,263.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 8 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.305 and the highest price at which shares were sold was $36.325. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 200 | $0.79 | $158.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 7 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 3,900 | $37.82 | $147,512.43 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 6 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.41 and the highest price at which shares were sold was $38.25. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 3,900 | $0.79 | $3,081.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 5 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,101 | $38.85 | $42,777.48 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 4 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.46 and the highest price at which shares were sold was $39.43. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4 and 5 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 1,101 | $0.79 | $869.79 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 100 | $39.52 | $3,952.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 100 | $0.79 | $79.00 |
DisclosureSEC source: 0001209191-18-053468 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 5,011 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · derivative · entry 6 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,870 Underlying: Common Stock · 5,011 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 4,989 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · derivative · entry 5 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,881 Underlying: Common Stock · 4,989 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCopmmon Stock | 5,011 | $38.79 | $194,363.66 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · nonDerivative · entry 4 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.50 and the highest price at which shares were sold was $39.30. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 5,011 | $0.79 | $3,958.69 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 4,989 | $38.02 | $189,703.73 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.465 and the highest price at which shares were sold was $38.37. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 4,989 | $0.79 | $3,941.31 |
DisclosureSEC source: 0001209191-18-041769 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 29, 2018 Filed Mar 29, 2018 20:23 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-022169 · doc4.xml · derivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,870 Underlying: Common Stock · 7,800 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 29, 2018 Filed Mar 29, 2018 20:23 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 7,800 | $0.79 | $6,162.00 |
DisclosureSEC source: 0001209191-18-022169 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · derivative · entry 6 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,670 Underlying: Common Stock · 300 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 300 | $0.79 | $237.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.